Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rabbit anti-T-lymphocyte globulin dosing to prevent GVHD in pediatric allogeneic stem cell transplantation
2006-004067-53Phase 3Active
- Sponsor
- IRCCS San Matteo Foundation
- Start
- Aug 2007
- Modality
- Recombinant Proteins and Enzymes, Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of antithymocyte globulin rabbit in acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and 2 more (4 arms), sponsored by IRCCS San Matteo Foundation. Primary endpoint: disease rejection. Started Aug 2007; status: active.
02
Drugs
antithymocyte globulin rabbit
03
Conditions
acute lymphoblastic leukemia (ALL)acute myeloid leukemia (AML)non-Hodgkin lymphoma (NHL)chronic myelogenous leukemia (CML)hematopoietic malignancies
Beyond the preview
Go deeper on 2006-004067-53.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-004067-53.